| Species | Gene ID | Accession | Source | Length | MW | Tag |
| Human | 4982 | O00300 | E. coli | 173aa | 19.7kDa | － |
| About this protein | |
| Name | Recombinant Human OPG (Recombinant Human Osteoprotegerin; rHuOPG)；重组人骨保护素 |
| Synonyms | OCIF; TNFRSF11B; OCIFMGC29565; OPGtumor necrosis factor receptor superfamily member 11B; Osteoclastogenesis inhibitory factor; Osteoprotegerin; osteoprotegerin; TR1; tumor necrosis factor receptor superfamily, member 11b |
| Purity | >95% by SDS-PAGE and HPLC analyses. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10ng/ml, corresponding to a specific activity of >1.0×105IU/mg in the presence of 10ng/ml soluble rHuRANKL (sRANKL). |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2μm filtered concentrated solution in 20mM PB,150mM NaCl, pH6.0. |
| Endotoxin | Less than 1EU/μg of rHuOPG as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions. |
| Category | Cytokine |
| Background | Osteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. OPG is a 401a.a. basic glycoprotein which comprises 7 structural domains. It is either a 60kDa monomer or a 120kDa dimer linked by disulfide bridges. OPG acts as a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro and may also play a role in preventing arterial calcification. OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases. Mature human OPG shares 86%, 87%, 92%, 92% and 88% amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively. |
| Amino Acid Sequence | ETFPPKYLHY DEETSHQLLC DKCPPGTYLK QHCTAKWKTV CAPCPDHYYT DSWHTSDECL YCSPVCKELQ YVKQECNRTH NRVCECKEGR YLEIEFCLKH RSCPPGFGVV QAGTPERNTV CKRCPDGFFS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK |
包装清单:
| 产品编号 | 产品名称 | 包装 |
| P5777-10μg | Recombinant Human OPG | 10μg |
| P5777-100μg | Recombinant Human OPG | 100μg |
| P5777-500μg | Recombinant Human OPG | 500μg |
| - | 说明书 | 1份 |
保存条件:
-20℃或更低温度保存，至少一年有效。由于蛋白的每次冻融均会引起部分失活，所以首次配制成相应浓度的储存液后(请根据产品简介中Reconstitution一栏的信息配制储存液)，须分装后-20℃或更低温度冻存，以避免反复冻融。
注意事项:
由于有些塑料管壁对某些蛋白有较强的吸附作用，溶液中的蛋白很容易粘附在管壁上，并且粘附后的蛋白很难与管壁分离。而载体蛋白(Carrier protein，如0.1% BSA等)的主要作用是预先封闭塑料管壁上的蛋白结合位点，使细胞因子或重组蛋白不会粘附于管壁。所以一定要使用产品简介中Reconstitution一栏的信息配制储存液。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
使用说明：
1. 收到产品后请立即按照说明书推荐的条件保存。除非特别注明，碧云天相关产品均为冻干粉，由于微量的蛋白在冻干过程中沉积在管内，形成很薄或不可见的蛋白层，所以在打开管盖前，我们建议在离心机中约8,000-12,000g离心10-30秒，使附着在管盖或管壁上的蛋白聚集于管底。
2. 请根据实验目的并按照产品简介中Reconstitution一栏中的信息配制储存液。大多数细胞因子或重组蛋白的冻干粉是非常容易溶解的，一般用移液枪的枪头轻吹几下或者轻轻摇晃瓶子，即可使细胞因子或重组蛋白完全溶解。请勿用vortex剧烈振荡，以免蛋白变性而失活。
3. 具体的最佳工作浓度请自行参考相关文献，或者根据实验目的，以及特定细胞和动物，通过实验进行摸索和优化。
